米国市場銘柄情報

ABBV アッヴィ

銘柄追加

160.810
-0.910-0.56%

終値 05/02 16:00 ET

162.000
+1.190+0.74%

市場前 08:44 ET

2,847.38億時価総額47.86直近PER

アッヴィに関するコメント

ログインコメントを投稿

Mars Mooo

04/21 16:13

My trading plan for April 2024 to July 2024.

Hello Mooers!

Recently, there have been signs that World War 3

is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task.

In light of this hypothetical situation

, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy.

Approach One: Buy the winners
Who are the winners?

During wars, companies that are in the defense, oil, ...

My trading plan for April 2024 to July 2024.

Moomoo x Nasdaq: Power up your trading with TotalView LV2

GarfieldNg

04/05 01:37

Wtf so big drop for tis week?

$アッヴィ(ABBV.US)$

Shaaaw

04/02 14:41

$ノボ・ノルディスク(NVO.US)$ & $イーライリリー(LLY.US)$ 's MCap increased by $285 bil in Q1 2024 alone, driven mostly by growth of the GLP-1 franchises,
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$アッヴィ(ABBV.US)$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...

Best Q1 since 2019: Bubble or bliss?

Meltyy

04/02 11:27

Major acquisition announced YTD in 2024

A look at one of the major acquisition deals YTD…👇
$MRTX
Acquired By: Bristol-Myers Squibb$ブリストル・マイヤーズスクイブ(BMY.US)$
Date: Jan. 23, 2024
Price: $4.8B
$アッヴィ(ABBV.US)$$GSK PLC(GSK.US)$

Meltyy

03/26 10:43

🔥 M&A News 🔥

$アッヴィ(ABBV.US)$ to acquire $ランドス・バイオファーマ(LABP.US)$
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$ニューベーション・バイオ(NUVB.US)$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$ノボ・ノルディスク(NVO.US)$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...

Moomoo AI

03/07 20:23

Richard Gonzalez's recent sale, despite a lower share price, suggests satisfaction with a lower valuation. High insider ownership but no insider buying in the last year raises caution.

Have Insiders Sold AbbVie Shares Recently?

areecep

03/07 14:21

All these stocks hit new 52 WEEK HIGHS at some point today

Nvidia $エヌビディア(NVDA.US)$
Walmart $ウォルマート(WMT.US)$
$アドバンスト・マイクロ・デバイス(AMD)(AMD.US)$
Costco $コストコホールセール(COST.US)$
Taiwan Semiconductor $タイワン・セミコンダクター・マニュファクチャリング(TSM.US)$
CrowdStrike $クラウドストライク(CRWD.US)$
JPMorgan $JPモルガン・チェース(JPM.US)$
Airbnb $エアビーアンドビー(ABNB.US)$
Palantir $パランティア・テクノロジーズ(PLTR.US)$
Qualcomm $クアルコム(QCOM.US)$
Target $ターゲット(TGT.US)$
Bank of America $バンク・オブ・アメリカ(BAC.US)$
Wells Fargo $ウェルズ・ファーゴ(WFC.US)$
Spotify $スポティファイ・テクノロジー(SPOT.US)$
...

Luzi Ann Santos

03/01 00:54

コラムIronwood Pharma Shares Tank 40% as Drug Trial Misses Secondary Goal

$アイアンウッド・ファーマシューティカルズ(IRWD.US)$ shares sank almost 40% after the drugmaker said its global phase III trial of Apraglutide, a treatment for short bowel syndrome, missed two of its four secondary goals.
That muddies the prospects for the company that's seeking to expand its product pipeline beyond Linzess.
Ironwood, which has been operating at a loss, sourced almost ll of its $117.6 million revenue in 2023 from its collaborati...

SpyderCall

02/29 09:11

It is starting to look like a double bottom on the weekly candles.

$ブリストル・マイヤーズスクイブ(BMY.US)$
The price action of BMY is finding support near the 47.50 price point. It appears to be forming a double bottom on the charts so far.
There is a bullish divergence on several of the popular oscillating indicators for the weekly candles. The major indicators for the daily candles, like RSI and MACD, are all officially in bullish territory.
Ultimately, the price would need to climb out of the trading ...

Moomoo News Global

02/28 19:28

コラムDon't Just Focus on AI! Biotech Stocks Are Rallying

Since the beginning of this year, $エヌビディア(NVDA.US)$ has been leading a group of semiconductor and AI stocks to further rise in response to the breakthroughs in AI technology and a booming industry outlook. However, an increasing number of investors have started to fret over the potential risks behind the high valuations of AI stocks and are scouting for alternative investment opportunities. Some of them have shifted their focus to biotech stocks...

NVIDIA's Q4 Earnings Blowout: Buy, sell or hold?

まだコメントはありません

分析

アナリスト評価

データなし

目標株価

データなし

ホット

米国株

総合人気